Crossmark

Timing of dose reduction matters: interpreting survival outcomes with CDK4/6 inhibitors in advanced breast cancer

Published Online: 2026-04-07

Authors

Altundag, Kadri
License Information

Text and Data Mining valid from 2026-04-07

Version of Record valid from 2026-04-07
More Information

Article History

Received: 28 January 2026

Accepted: 24 March 2026

First Online: 7 April 2026

Declarations

:

: The authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current